Status:
COMPLETED
Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus
Lead Sponsor:
Besins Healthcare
Conditions:
T2DM (Type 2 Diabetes Mellitus)
Hypogonadism
Eligibility:
MALE
45-60 years
Brief Summary
The purpose of the study is to get data of prevalence of testosterone deficiency in patient with T2DM in Russian Federation
Detailed Description
Clinical and Epidemiological Characteristics and Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus Under Routine Clinical Practice (DESTINY)
Eligibility Criteria
Inclusion
- Male 45-60 years old
- Diagnosis of T2DM according to approved standards
- Signed Informed Consent Form
Exclusion
- Prepubertal hypogonadism of any genesis;
- Sexual and developmental disorders;
- Absence of at least one of the testicles;
- Cryptorchidism, including in the anamnesis;
- Injuries and / or surgical interventions on the genitals with loss of at least one of the testicles;
- Established diagnosis of panhypopituitarism in accordance with current recommendations / standards;
- Androgen therapy, administered at the time of the study or in the anamnesis;
- Admission of anabolic steroids;
- Alcoholism or drug addiction;
- Insolvency.
Key Trial Info
Start Date :
December 6 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
554 Patients enrolled
Trial Details
Trial ID
NCT03437109
Start Date
December 6 2017
End Date
February 1 2019
Last Update
June 20 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ENC
Moscow, Russia, 117036
2
Central Clinical Hospital
Moscow, Russia, 121359